Mela Sciences Inc (MELA) 1.55 $MELA
Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets
M2 - Thu Feb 05, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mh8jd/point_of_care) has announced the addition of the "Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets" report to their offering. The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Selection of 30 Companies: Click the link below to view the full extensive list featured in this report - Abaxis, Inc. - Abbott Laboratories - Acrongenomics - AgaMatrix - Augurix Diagnostics Ltd. - Axis-Shield Plc (Alere) - Axxin - Bayer Corp - Chembio Diagnostic, Inc. - Home Diagnostics (Nipro Diagnostics) - Medix Biochemica - MedMira Laboratories - MELA Sciences (Formerly Electro-Optical Sciences) - A. Menarini Diagnostics - Meretek Diagnostics Group - Nexus/ITC - Nova Biomedical - OraSure Technologies, Inc. - Orion Diagnostica - Polymedco, Inc. - Polymer Technology Systems, Inc. - Prima Biomedical Company - QBC Diagnostics - Qualigen - Selfcare, Inc. - Shanghai Ruicare Medical Co., Ltd. - Shenzhen Fitconn Technology Co., Ltd. - Siemens AG - Siloam Biosciences, Inc. - V?samed, Inc. For more information visit http://www.researchandmarkets.com/research/2m...nt_of_care
ABT: 46.09 (+0.87), MELA: 1.55 (+0.09), ABAX: 60.93 (+0.65), OSUR: 8.13 (+0.06)
MELA Sciences CEO Michael R. Stewart to Present at the Eighth Annual OneMedForum January 13 at 2 p.m.
GlobeNewswire - Thu Jan 08, 5:07PM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind(R) system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that MELA Sciences' CEO Michael R. Stewart will present at the OneMedForum at the Marriott Marquis, San Francisco on January 13 at 2:00 p.m. PST.
MELA: 1.55 (+0.09)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 11:50AM CST
JBSS: 37.24 (-0.26), MELA: 1.55 (+0.09), SYRX: 1.50 (-0.06), NRX: 6.67 (-0.14), NKA: 1.68 (+0.13), PRTK: 26.95 (+0.65), JOB: 0.79 (+0.01), HNR: 0.69 (+0.03), BCLI: 3.86 (-0.02), QTWW: 2.96 (-0.04), CHNR: 1.91 (+0.01), PWRD: 18.95 (+0.02), CJJD: 2.59 (-0.01), WTW: 18.16 (+0.33), LOCK: 14.10 (-0.19), MDXG: 8.65 (+0.23), GNI: 10.94 (+0.15), ATEA: 1.76 (+0.01), EXEL: 2.48 (+0.20)
Mela Sciences up in early trading
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 10:45AM CST
MELA: 1.55 (+0.09)
MELA Sciences elects Michael R. Stewart as its CEO
M2 - Thu Nov 20, 5:43AM CST
Software image analysis company MELA Sciences (NasdaqCM:MELA) reported on Wednesday the appointment of Michael R. Stewart as its president and chief executive officer with effect from 15 December 2014.
MELA: 1.55 (+0.09)
MELA Sciences Names Michael R. Stewart Its Next President and CEO
GlobeNewswire - Wed Nov 19, 7:07AM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that its Board of Directors has named Michael R. Stewart, 57, as the company's next President and Chief Executive Officer, effective December 15. Mr. Stewart, who joined the MELA Sciences Board of Directors in August 2014, will remain a member of the board.
MELA: 1.55 (+0.09)
MELA Sciences announces 69% drop in net loss in Q3 2014
M2 - Fri Nov 14, 6:29AM CST
Medical device company MELA Sciences (NasdaqCM:MELA) stated on Thursday its net loss of USD2.3m (USD0.44 per basic and diluted share) for the three months ended 30 September 2014.
MELA: 1.55 (+0.09)
MELA Sciences' (MELA) CEO Rose Crane on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 8:59PM CST
MELA: 1.55 (+0.09)
MELA Sciences EPS of -$0.44
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:08PM CST
MELA: 1.55 (+0.09)
MELA Sciences Reports Third Quarter 2014 Financial Results
GlobeNewswire - Wed Nov 12, 3:06PM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFindsystem, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), today announced financial results for the three and nine months ended September 30, 2014.
MELA: 1.55 (+0.09)
MELA Sciences to Report Third Quarter 2014 Financial Results on Wednesday, November 12
GlobeNewswire - Wed Nov 05, 7:00AM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of MelaFind, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), will release third quarter 2014 financial results on Wednesday, November 12, after the market close. MELA Sciences President and Chief Executive Officer, Rose Crane, and Robert Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.55 (+0.09)
Outcomes Study Reports Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanoma
GlobeNewswire - Tue Oct 21, 7:01AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of MelaFind, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), today announced that highly favorable results were obtained in a study using MelaFind to assess lesions in patients at risk for melanoma. The results were included in the 2013 Outcomes for Cleveland Clinic's Dermatology & Plastic Surgery Institute, which was recently released.
MELA: 1.55 (+0.09)
MELA Sciences to Provide Corporate Overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conference
GlobeNewswire - Mon Sep 15, 7:00AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, a non-invasive optical diagnostic tool that assists dermatologists in the diagnosis of melanoma at its most curable and cost-effective stage and that has received both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union, today announced that MELA CEO Rose Crane will provide a corporate overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conference in New York City.
MELA: 1.55 (+0.09)
MELA Sciences to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 08, 11:04AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, a non-invasive optical diagnostic tool that assists dermatologists in the diagnosis of melanoma at its most curable and cost-effective stage and that has received both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union, today announced that MELA CEO Rose Crane will provide a corporate overview at the Rodman & Renshaw 16 Annual Global Investment Conference taking place September 8-10 in New York City.
MELA: 1.55 (+0.09)
MELA Sciences Collaborates With Columbia University Imaging Experts
GlobeNewswire - Tue Aug 26, 7:07AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, a non-invasive optical diagnostic tool that assists dermatologists in the diagnosis of melanoma at its most curable and cost-effective stage and that has received both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union, today announced it has executed a research agreement with Columbia University in which MELA and Columbia will collaborate to explore potential next generation capabilities and features of the MelaFind system and other enhancements to the system's range and ease of use.
MELA: 1.55 (+0.09)
MELA Sciences Reports Second Quarter 2014 Financial Results and Provides a Business Update
GlobeNewswire - Wed Aug 13, 3:01PM CDT
MELA Sciences, Inc. (Nasdaq:MELA) (the Company), developer of the MelaFind system, a non-invasive optical diagnostic tool that assists dermatologists in the diagnosis of melanoma at its most curable and cost-effective stage and that has received both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union, today announced financial results for the three and six months ended June 30, 2014. The Company also provided a business update.
MELA: 1.55 (+0.09)
MELA Sciences to Host Analyst Meeting and Webcast on Wednesday, August 13 in New York City
GlobeNewswire - Thu Aug 07, 8:31AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will host an analyst breakfast on Wednesday, August 13, 2014 from 8:00 a.m. to 9:30 a.m. Eastern time in New York City. The event will feature a presentation by Darrell S. Rigel, MD, a Clinical Professor of Dermatology at NYU Langone Medical Center. Rose Crane, President and CEO of MELA Sciences, will also provide an overview of the Company as well as its lead product, the MelaFind System.
MELA: 1.55 (+0.09)
MELA Sciences Names Michael R. Stewart to Board of Directors
GlobeNewswire - Tue Aug 05, 8:00AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced it has named Michael R. Stewart to its board of directors effective immediately. Mr. Stewart is an independent director.
MELA: 1.55 (+0.09), PHMD: 1.68 (+0.04)
MELA Sciences to Report Second Quarter 2014 Financial Results on Wednesday, August 13
GlobeNewswire - Mon Aug 04, 3:01PM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will release second quarter 2014 financial results on Wednesday, August 13, after the market close. MELA Sciences President and Chief Executive Officer, Rose Crane, and Chief Financial Officer, Robert Cook, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.55 (+0.09)
MELA Sciences Regains Compliance With NASDAQ Listing Requirements
GlobeNewswire - Tue Jul 29, 7:00AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that it has received a letter from The NASDAQ Stock Market advising that the Company has regained compliance with NASDAQ's minimum bid price listing requirement.
MELA: 1.55 (+0.09)
Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets
M2 - Thu Feb 05, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mh8jd/point_of_care) has announced the addition of the "Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets" report to their offering. The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Selection of 30 Companies: Click the link below to view the full extensive list featured in this report - Abaxis, Inc. - Abbott Laboratories - Acrongenomics - AgaMatrix - Augurix Diagnostics Ltd. - Axis-Shield Plc (Alere) - Axxin - Bayer Corp - Chembio Diagnostic, Inc. - Home Diagnostics (Nipro Diagnostics) - Medix Biochemica - MedMira Laboratories - MELA Sciences (Formerly Electro-Optical Sciences) - A. Menarini Diagnostics - Meretek Diagnostics Group - Nexus/ITC - Nova Biomedical - OraSure Technologies, Inc. - Orion Diagnostica - Polymedco, Inc. - Polymer Technology Systems, Inc. - Prima Biomedical Company - QBC Diagnostics - Qualigen - Selfcare, Inc. - Shanghai Ruicare Medical Co., Ltd. - Shenzhen Fitconn Technology Co., Ltd. - Siemens AG - Siloam Biosciences, Inc. - V?samed, Inc. For more information visit http://www.researchandmarkets.com/research/2m...nt_of_care
ABT: 46.09 (+0.87), MELA: 1.55 (+0.09), ABAX: 60.93 (+0.65), OSUR: 8.13 (+0.06)
MELA Sciences CEO Michael R. Stewart to Present at the Eighth Annual OneMedForum January 13 at 2 p.m.
GlobeNewswire - Thu Jan 08, 5:07PM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind(R) system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that MELA Sciences' CEO Michael R. Stewart will present at the OneMedForum at the Marriott Marquis, San Francisco on January 13 at 2:00 p.m. PST.
MELA: 1.55 (+0.09)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 11:50AM CST
JBSS: 37.24 (-0.26), MELA: 1.55 (+0.09), SYRX: 1.50 (-0.06), NRX: 6.67 (-0.14), NKA: 1.68 (+0.13), PRTK: 26.95 (+0.65), JOB: 0.79 (+0.01), HNR: 0.69 (+0.03), BCLI: 3.86 (-0.02), QTWW: 2.96 (-0.04), CHNR: 1.91 (+0.01), PWRD: 18.95 (+0.02), CJJD: 2.59 (-0.01), WTW: 18.16 (+0.33), LOCK: 14.10 (-0.19), MDXG: 8.65 (+0.23), GNI: 10.94 (+0.15), ATEA: 1.76 (+0.01), EXEL: 2.48 (+0.20)
Mela Sciences up in early trading
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 10:45AM CST
MELA: 1.55 (+0.09)
MELA Sciences elects Michael R. Stewart as its CEO
M2 - Thu Nov 20, 5:43AM CST
Software image analysis company MELA Sciences (NasdaqCM:MELA) reported on Wednesday the appointment of Michael R. Stewart as its president and chief executive officer with effect from 15 December 2014.
MELA: 1.55 (+0.09)
MELA Sciences Names Michael R. Stewart Its Next President and CEO
GlobeNewswire - Wed Nov 19, 7:07AM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that its Board of Directors has named Michael R. Stewart, 57, as the company's next President and Chief Executive Officer, effective December 15. Mr. Stewart, who joined the MELA Sciences Board of Directors in August 2014, will remain a member of the board.
MELA: 1.55 (+0.09)
MELA Sciences announces 69% drop in net loss in Q3 2014
M2 - Fri Nov 14, 6:29AM CST
Medical device company MELA Sciences (NasdaqCM:MELA) stated on Thursday its net loss of USD2.3m (USD0.44 per basic and diluted share) for the three months ended 30 September 2014.
MELA: 1.55 (+0.09)
MELA Sciences' (MELA) CEO Rose Crane on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 8:59PM CST
MELA: 1.55 (+0.09)
MELA Sciences EPS of -$0.44
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:08PM CST
MELA: 1.55 (+0.09)
MELA Sciences Reports Third Quarter 2014 Financial Results
GlobeNewswire - Wed Nov 12, 3:06PM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFindsystem, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), today announced financial results for the three and nine months ended September 30, 2014.
MELA: 1.55 (+0.09)
MELA Sciences to Report Third Quarter 2014 Financial Results on Wednesday, November 12
GlobeNewswire - Wed Nov 05, 7:00AM CST
MELA Sciences, Inc. (Nasdaq:MELA), developer of MelaFind, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), will release third quarter 2014 financial results on Wednesday, November 12, after the market close. MELA Sciences President and Chief Executive Officer, Rose Crane, and Robert Cook, Chief Financial Officer, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.55 (+0.09)
Outcomes Study Reports Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for Melanoma
GlobeNewswire - Tue Oct 21, 7:01AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of MelaFind, a non-invasive software-driven image analysis device intended to provide a dermatologist with objective data of clinically irregular pigmented moles when they choose to obtain additional info to help them decide whether or not to biopsy (at the most curable and cost-effective stage), today announced that highly favorable results were obtained in a study using MelaFind to assess lesions in patients at risk for melanoma. The results were included in the 2013 Outcomes for Cleveland Clinic's Dermatology & Plastic Surgery Institute, which was recently released.
MELA: 1.55 (+0.09)
MELA Sciences to Provide Corporate Overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conference
GlobeNewswire - Mon Sep 15, 7:00AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, a non-invasive optical diagnostic tool that assists dermatologists in the diagnosis of melanoma at its most curable and cost-effective stage and that has received both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union, today announced that MELA CEO Rose Crane will provide a corporate overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conference in New York City.
MELA: 1.55 (+0.09)
MELA Sciences to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 08, 11:04AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, a non-invasive optical diagnostic tool that assists dermatologists in the diagnosis of melanoma at its most curable and cost-effective stage and that has received both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union, today announced that MELA CEO Rose Crane will provide a corporate overview at the Rodman & Renshaw 16 Annual Global Investment Conference taking place September 8-10 in New York City.
MELA: 1.55 (+0.09)
MELA Sciences Collaborates With Columbia University Imaging Experts
GlobeNewswire - Tue Aug 26, 7:07AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, a non-invasive optical diagnostic tool that assists dermatologists in the diagnosis of melanoma at its most curable and cost-effective stage and that has received both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union, today announced it has executed a research agreement with Columbia University in which MELA and Columbia will collaborate to explore potential next generation capabilities and features of the MelaFind system and other enhancements to the system's range and ease of use.
MELA: 1.55 (+0.09)
MELA Sciences Reports Second Quarter 2014 Financial Results and Provides a Business Update
GlobeNewswire - Wed Aug 13, 3:01PM CDT
MELA Sciences, Inc. (Nasdaq:MELA) (the Company), developer of the MelaFind system, a non-invasive optical diagnostic tool that assists dermatologists in the diagnosis of melanoma at its most curable and cost-effective stage and that has received both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union, today announced financial results for the three and six months ended June 30, 2014. The Company also provided a business update.
MELA: 1.55 (+0.09)
MELA Sciences to Host Analyst Meeting and Webcast on Wednesday, August 13 in New York City
GlobeNewswire - Thu Aug 07, 8:31AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will host an analyst breakfast on Wednesday, August 13, 2014 from 8:00 a.m. to 9:30 a.m. Eastern time in New York City. The event will feature a presentation by Darrell S. Rigel, MD, a Clinical Professor of Dermatology at NYU Langone Medical Center. Rose Crane, President and CEO of MELA Sciences, will also provide an overview of the Company as well as its lead product, the MelaFind System.
MELA: 1.55 (+0.09)
MELA Sciences Names Michael R. Stewart to Board of Directors
GlobeNewswire - Tue Aug 05, 8:00AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced it has named Michael R. Stewart to its board of directors effective immediately. Mr. Stewart is an independent director.
MELA: 1.55 (+0.09), PHMD: 1.68 (+0.04)
MELA Sciences to Report Second Quarter 2014 Financial Results on Wednesday, August 13
GlobeNewswire - Mon Aug 04, 3:01PM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will release second quarter 2014 financial results on Wednesday, August 13, after the market close. MELA Sciences President and Chief Executive Officer, Rose Crane, and Chief Financial Officer, Robert Cook, will host a conference call at 4:30pm Eastern Time to review the Company's progress and answer questions.
MELA: 1.55 (+0.09)
MELA Sciences Regains Compliance With NASDAQ Listing Requirements
GlobeNewswire - Tue Jul 29, 7:00AM CDT
MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that it has received a letter from The NASDAQ Stock Market advising that the Company has regained compliance with NASDAQ's minimum bid price listing requirement.
MELA: 1.55 (+0.09)
